Jump to content

PEB - PACIFIC EDGE LIMITED


ShareCafe
 Share

Recommended Posts

  • 3 weeks later...
  • Replies 205
  • Created
  • Last Reply

Top Posters In This Topic

  • 2 weeks later...

I think this is what the big secret is in PEB. I would say they have devised their own version of it to their own IP suite.

 

http://www.rii.com/publications/2001/nb200104Hughes.html

 

Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer

 

Timothy R. Hughes, Mao Mao, Allan R. Jones, Julja Burchard, Matthew J. Marton, Karen W. Shannon, Steven M. Lefkowitz, Michael Ziman, Janell M. Schelter, Michael R. Meyer, Sumire Kobayashi, Colleen Davis, Hongyue Dai, Yudong D. He, Sergey B. Stephaniants, Guy Cavet, Wynn L. Walker, Anne West, Ernest Coffey, Daniel D. Shoemaker, Roland Stoughton, Alan P. Blanchard, Stephen H. Friend, and Peter S. Linsley

 

Abstract

 

We describe a flexible system for gene expression profiling using arrays of tens of thousands of oligonucleotides synthesized in situ by an ink-jet printing method employing standard phosphoramidite chemistry. We have characterized the dependence of hybridization specificity and sensitivity on parameters including oligonucleotide length, hybridization stringency, sequence identity, sample abundance, and sample prepara-tion method. We find that 60-mer oligonucleotides reliably detect transcript ratios at one copy per cell in complex biological samples, and that ink-jet arrays are compatible with several different sample amplification and labeling techniques. Furthermore, results using only a single carefully selected oligonucleotide per gene correlate closely with those obtained using complementary DNA (cDNA) arrays. Most of the genes for which measurements differ are members of gene families that can only be distinguished by oligonucleotides. Because different oligonucleotide sequences can be specified for each array, we anticipate that ink-jet oligonucleotide array technology will be useful in a wide variety of DNA microarray applications.

 

 

Link to comment
Share on other sites

  • 1 month later...

Is that you steadily bidding up the price with small buys, Plastic?

 

Well, at least it's good to see a bit of activity in PEB. Results on second validation of melanoma predictor must be due - was expected completion in October as at Annual Report. Oh and half year report due end of this month. So maybe a bit of newsflow will garner more interest. Then it's back to waiting for the bladder cancer test result in first half of 2009.

Link to comment
Share on other sites

Is that you steadily bidding up the price with small buys, Plastic?

 

No. Not me. But interesting their melanoma test is due soon. I was watching TV3 late night news yesterday and melanoma got a blurb on that. Although that was about a vaccine of the Gardisil type.

Link to comment
Share on other sites

  • 2 weeks later...

Half Year report out yesterday.

 

The good - licencing revenue from Signature Diagnostics, Colo-rectal trial on track for March completion, Bladder cancer trial on track for August Completion. More revenues from Signature then in Mar/April on completion of trial and already in negotiations with "blue chip US company" for licensing of the bladder cancer test post-trial.

 

The bad - burned through half the cash in six months and won't see new licensing revenue until around April, so is going to be running tight again although directors have previously said they raised enough to get to commercial. 'Twill be a challenge. Then will need a far more significant amount than the $171k revenue of this half to see them through to a post-trial licensing payment from a US blue chip.

 

Melanoma and Gastric didn't rate a mention - not unusual for PEB to drop mention of things for a while, so I doubt that means anything.

 

Overall, progress looks steady and a good chance that PEB can start to generate some more serious commercial revenue from April onwards. However, it is still not possible to gauge value - delays are almost compulsory in this field which means more potential dilution and the magnitude of potential revenues is guesswork. Valuation of biotech licensing often appears quite erratic to me!

Link to comment
Share on other sites

This is interesting - OncoMethylome Sciences

 

Don't remember coming across this one before - seem like competition in both colo-rectal and bladder cancer diagnostics, though perhaps running a little behind and not obvious that their technology is advantageous over PEB. Still, interesting that they are also working with Signature and in fact have taken a small equity stake in them. Plus, of course, they have a much larger budget, cash backing and equity value to draw on.

Link to comment
Share on other sites

  • 2 months later...
 Share


×
×
  • Create New...